Compare Newmont Corporation (NEM) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Novo Nordisk A/S — how do they compare? Newmont Corporation trades at $118.33 (market cap $123.50B), while Novo Nordisk A/S trades at $46.19 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NEM | NVO | |
|---|---|---|
Market Cap | $123.50B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $63.98 |
52-Week Low | $67.38 | $35.29 |
Enterprise Value | $120.09B | $222.55B |
Dividend Yield | 0.89% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $119.12, up 1.59% with strong technical momentum as it approaches resistance near $120. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.10 versus $2.05 forecast, continuing a trend of earnings outperformance. Revenue growth accelerated to $22.67 billion in 2025 with net income margin expanding to 33.36%. Recent news highlights resolution of Nevada disputes with Barrick Mining and strong gold price environment supporting miner profitability.
Outlook remains positive with analyst consensus price target of $133 representing 11.6% upside potential. Key opportunities include continued gold price strength and operational efficiency gains, while risks involve potential cost inflation and gold price volatility. With 76% analyst buy ratings and improving cash flow trends, NEM appears well-positioned for continued growth in the current commodity cycle.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
